Non-Hodgkin lymphoma
Indolent versus aggressive NHL, the infections and immune states behind them, excision biopsy and PET staging, IPI and FLIPI, R-CHOP and Pola-R-CHP for DLBCL, CAR-T and bispecifics at relapse, watch and wait in follicular lymphoma, mantle cell, marginal zone, Burkitt, Waldenström and T-cell lymphomas.
Tier 1Condition
Written with AI assistance and fact-checked against the sources below. For exam study, not clinical decisions. How notes are made
At a glance
- A diverse group: about 85 to 90% are B-cell. DLBCL (about a third) and follicular lymphoma (about a fifth) are the commonest.
- Think in two groups. Aggressive lymphomas (DLBCL, Burkitt, most T-cell) grow over weeks and are often curable. Indolent lymphomas (follicular, marginal zone, small lymphocytic, lymphoplasmacytic) grow over years, respond well, but usually relapse.
- Diagnosis needs tissue, ideally an excision biopsy. Stage with PET/CT.
Loading the rest of the note…
Finished reading?
Sources
- Large B-cell lymphoma (LBCL): EHA Clinical Practice Guidelines for diagnosis, treatment, and follow-upThieblemont C et al., European Hematology Association, HemaSphere 2025, 2025
- Newly diagnosed and relapsed follicular lymphoma: EHA Clinical Practice Guidelines for diagnosis, treatment, and follow-upLadetto M et al., European Hematology Association, HemaSphere 2026, 2026
- EHA-EU MCL network guidelines for diagnosis and treatment of mantle cell lymphomaJerkeman M et al., HemaSphere 2025, 2025
- Management of relapsed or refractory large B-cell lymphoma: A British Society for Haematology GuidelineChaganti S et al., Br J Haematol 2025, 2025
- Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classificationCheson BD et al., J Clin Oncol 2014;32:3059-68, 2014
- Optimal care pathway for people with Hodgkin and diffuse large B-cell lymphomas, 2nd editionAU/NZCancer Council Australia
- eviQ Haematology and BMT treatment protocols, lymphomaAU/NZCancer Institute NSW
- Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma (POLARIX)Tilly H et al., N Engl J Med 2022;386:351-63, 2022
- Schedule of Pharmaceutical Benefits, November 2026 (obinutuzumab, glofitamab, epcoritamab, tafasitamab, zanubrutinib, mogamulizumab)AU/NZAustralian Government Department of Health, Disability and Ageing, November 2026
- Last updated
- 14 November 2026
What changed
- 14 November 2026 Turnstile bot check on sign-in and signed-out feedback